Ibrance (Palbociclib)

Palbociclib selectively inhibits cyclin‑dependent kinases 4 and 6, which are essential for progression from the G1 to S phase of the cell cycle. By blocking these kinases, the drug halts proliferation of cancer cells that rely on this pathway, thereby slowing tumor growth.

The prescribed dose of Ibrance is determined by the treating physician based on the patient’s clinical condition, concomitant medications, and laboratory values. Dosage adjustments may be required for blood‑count changes or organ impairment, and the prescriber provides the specific regimen.

Palbociclib is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and effective contraception is required for women of child‑bearing potential. Safety during breastfeeding has not been established, and nursing mothers should avoid the drug.

To request Ibrance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ibrance (palbociclib) is one of several CDK4/6 inhibitors, alongside ribociclib and abemaciclib. All target the same kinases, but they differ in dosing schedules, side‑effect profiles, and specific approvals. Choice of therapy depends on physician assessment of efficacy, tolerability, and patient characteristics.

Ibrance tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the medication out of reach of children and do not store in the bathroom or other humid environments.

Ibrance is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet is swallowed whole with a glass of water, and the dosing cycle typically follows a 21‑day on‑treatment period followed by a 7‑day break, although the exact schedule is set by the physician.

The most serious risks include severe neutropenia, febrile neutropenia, and life‑threatening infections. Patients should be monitored regularly for blood‑cell counts, and any signs of fever, infection, or unusual bleeding should prompt immediate medical evaluation.

Ibrance is contraindicated in pregnant women and should not be used in patients with known hypersensitivity to palbociclib or any tablet components. Caution is also advised for individuals with severe liver impairment, uncontrolled infections, or those receiving strong CYP3A4 inducers that could reduce drug efficacy.